CENTER FOR BREAKTHROUGH MEDICINES

Live / Registered — Registered (as of 08 Jun 2021)

What this means for you

Registered since 08 Jun 2021. The owner can stop confusingly similar uses in the classes it covers.

Record

Serial number
88981530
Registration number
6382057
Mark type
Stylized text
Filed
12 Dec 2019
Published for opposition
12 Jan 2021
Registered
08 Jun 2021
Attorney of record
Joshua M. Gerben, Esq.

Goods and services

  • Class 040 — Treatment of materials: Manufacturing services for others in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; manufacturing services for others in the fields of mammalian cell banks, plasmids, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; manufacturing process consulting
  • Class 042 — Scientific and technological services: Research and development services in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; consulting services in the fields of research and development for gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; research and development of new products for others; process development services in the nature of research and development of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; scientific research and technical research services, namely, production of cell lines for others using lentivirus technology; scientific research and technical research services relating to producing, assaying and purifying recombinant or manipulated lentivirus; Scientific and technical consulting services relating to producing, assaying, and purifying adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; advisory services relating to research and development of gene therapy products and biopharmaceuticals; manufacturing support services for others, namely, cGMP (Current Good Manufacturing Practice) quality control testing in support of biopharmaceutical development and manufacturing; quality control for others; quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; material testing; product quality testing; scientific laboratory services; scientific research

Owner

Prosecution history

  • 19 Oct 2022 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
  • 08 Jun 2021 — REGISTERED-PRINCIPAL REGISTER
  • 06 May 2021 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
  • 05 May 2021 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
  • 03 May 2021 — STATEMENT OF USE PROCESSING COMPLETE
  • 05 Apr 2021 — USE AMENDMENT FILED
  • 03 May 2021 — DIVISIONAL PROCESSING COMPLETE
  • 05 Apr 2021 — DIVISIONAL REQUEST RECEIVED
  • 26 Apr 2021 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
  • 05 Apr 2021 — TEAS STATEMENT OF USE RECEIVED
  • 05 Apr 2021 — TEAS REQUEST TO DIVIDE RECEIVED
  • 09 Mar 2021 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
  • 12 Jan 2021 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 12 Jan 2021 — PUBLISHED FOR OPPOSITION
  • 23 Dec 2020 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

View this trademark record on Marksy